Unlocking the true power of PET

A powerful new platform to diagnose, study, and treat disease

Radiopharmaceuticals for the modern world

We are working to improve the scope, safety, use, and cost of PET imaging.

PET scans are critical for detecting and diagnosing disease in clinical settings, but their true potential remains largely untapped.

Outline of brain tissues, few details
Outline of brain tissues, more details
Outline of brain tissues, lot of details

A single, disease-agnostic platform that scales

We make it possible to rapidly produce a broad range of fluorine-18 radiopharmaceuticals based on a single, catalyst-driven, disease-agnostic chemistry platform.

Our patented HetSiFA™ compositions, synthesized using our alkali metal catalysts, can attach to disease-targeting ligands at record-breaking speed.

Other features of our platform further simplify and shorten the radiopharmaceutical manufacturing process. Our chemistry can occur at room temperature, in aqueous solution, without metallic additives, and with no HPLC purification.

Learn More

Solving for existing challenges

Manufacturing Limitations for Targeted Pharmaceuticals
Icon for problems row Diagnostic Limitations of RP’s
Icon for solutions row FDx Developing a Suite of Targeted RP’s
Clock symbol Very long
development time
Radio symbol Ultrafast radiolabelling
Chemical conditions symbol 1 Specific chemical
conditions required
Chemical conditions symbol 1 Clinically relevant conditions
Galium in periodic table Limitations of alternative radionuclides
Radiopharmaceuticals symbol Safer 18F-based radiopharmaceuticals
C-F bond symbol Challenging C-F bond
synthesis
Si-F bond symbol Facile Si‑F bond synthesis
Si-F bond symbol Stability issues with
Si‑F bonds
100% percent HetSiFA™ approach has close to 100% stability
Fuzionaire Diagnostics’ chemistry addresses the existing challenges
Drugs and pills

Accelerating drug discovery

Valuable from the earliest stages of drug discovery, PET imaging of new drug candidates provides unique pharmacokinetic information and quantification of drug properties in vivo. Our radiolabeling platform can make PET a ubiquitous, essential, and cost-effective tool that improves decision-making and increases returns on R&D investment throughout all stages of the drug development process.

Our science

We apply Fuzionaire’s core chemistry, based on alkali metal catalysts, to make new radiotracers.

Read More

Our collaborators

We are proud to partner with world-class institutions unlocking the power of molecular science. Together, we are building a better future by expanding the possibilities of chemistry and its applications.

Get in touch

If you are interested in learning more about our radiolabeling platform, we want to hear from you.

Contact